A National, Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients With Chronic Idiopathic Constipation

Trial Profile

A National, Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients With Chronic Idiopathic Constipation

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Plecanatide (Primary)
  • Indications Constipation
  • Focus Registrational; Therapeutic Use
  • Acronyms National CIC3
  • Sponsors Synergy Pharmaceuticals Inc
  • Most Recent Events

    • 24 May 2017 Results (n=2683) assessing impact of Plecanatide on quality of life for patients with chronic idiopathic constipation using patient data from two phase 3 clinical studies (CIC3 and National CIC3), presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
    • 09 May 2017 Results (n=3536) assessing placebo relative effect of Linaclotide and Plecanatide on efficacy and safety using patient data pooled from 4 phase 3 trials (NCT00730015, NCT00765882, NCT01982240, NCT02122471), presented at the Digestive Disease Week 2017
    • 09 May 2017 Results (n=2683) assessing efficacy of Plecanatide in decreaseing the severity of straining, abdominal bloating, and abdominal discomfort in patients, presented at the Digestive Disease Week 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top